nafamostat has been researched along with apilimod in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Balistreri, G; Kirchhausen, T; Kreutzberger, AJB; Ojha, R; Pyle, JD; Sanyal, A; Vapalahti, O | 1 |
2 other study(ies) available for nafamostat and apilimod
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
Topics: Animals; Antiviral Agents; Benzamidines; Cell Line, Tumor; Chlorocebus aethiops; COVID-19 Drug Treatment; Drug Synergism; Esters; Guanidines; Humans; Hydrazones; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protease Inhibitors; Pyrimidines; SARS-CoV-2; Serine Endopeptidases; Vero Cells; Virus Internalization | 2021 |